Johnson & Johnson has announced that its drug nipocalimab demonstrated statistically significant and clinically meaningful improvements in a Phase II study for 18 June 2024
Kite, a Gilead Sciences company, has unveiled new analyses for Yescarta (axicabtagene ciloleucel) in relapsed/refractory large B-cell lymphoma (LBCL). 14 June 2024
Belgium’s UCB is sharing results from three studies supporting the value of Cimzia (certolizumab pegol) for women of childbearing age living with chronic immune 13 June 2024
One of the most important medical meetings in rheumatology is underway in Vienna, Austria, and leading drugmakers in the field have lifted the lid on data they 12 June 2024
Belgian biotech UCB has presented promising two-year data from Phase III studies on Bimzelx (bimekizumab) at the European Congress of Rheumatology, EULAR 2024. 12 June 2024
Gilead Sciences has announced data from the Phase IIb MYR204 open-label study assessing the first-in-class entry inhibitor bulevirtide as monotherapy and in com 6 June 2024
US biotech major Gilead Sciences has announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary 5 June 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.